Lantheus Holdings + 9.79% Proves Experts Wrong With Q1 2016 Results

Destiny A. Lopez  |

The world of finance is a challenging environment. No matter how large or small, business across a variety of sectors are being analyzed in regards to performance, opportunity, and so on. Not only do organizations have to internally address the daily ups and downs that are expected in business; companies also have to address projections, both bad and good, by finance analysts and experts. It must be a sigh of relief when a company gets to report financials that are not only positive; but also prove the experts wrong. Lantheus Holdings (LNTH), the parent company of leading diagnostic image agents and products provider, Lantheus Medical Imaging, get to do just that with their latest announcement.

The Massachusetts-based company, up 9.79% today, recently released its Q1 2016 financial results. The report revealed a $10.3 million profit, along with, despite three analysts surveyed by Zacks projecting $71.9 million in revenue, the company surpassed expectations with $76.5 million in worldwide revenue, a 2% increase over Q1 2015.

“We had a strong quarter, exceeding both our first quarter revenue and Adjusted EBITDA guidance,” said Mary Anne Heino, President and CEO of Lantheus. “Our robust results were driven by continued excellent performance of DEFINITY® in an increasingly competitive market and higher than forecasted sales of our nuclear products. We are pleased to be raising our annual revenue and Adjusted EBITDA guidance despite the recent entrance into the U.S. market of a competitor to our Xenon product.”

Founded in 1956, Lantheus is committed to providing medical imaging solutions that aide in and improve the treatment of various diseases.

According to its official website, the company’s imaging solutions portfolio include:

  • DEFINITY®, the leading ultrasound contrast agent used in ultrasound exams of the heart.
  • ABLAVAR®, a first-in-class magnetic resonance agent used in the evaluation of aortoiliac occlusive disease in adults.
  • Cardiolite®, a cardiac imaging agent.
  • TechneLite®, a technetium-based generator.

Furthermore, good news has been no stranger to Lantheus in recent months. In April, promising new data from the company’s Flurpiridaz F 18 First Phase 3 Study was presented at the American College of Cardiology’s Annual Scientific Session. "The Phase 3 data sub-analysis presented at ACC show the advantages of flurpiridaz F 18 PET imaging for coronary artery disease detection in obese patients,” said Cesare Orlandi, M.D., Chief Medical Officer of Lantheus Medical Imaging. “Flurpiridaz F 18 PET imaging shows superiority over SPECT in an obese population and provides images with better quality, and less attenuation, which can lead to increased diagnostic certainty by physicians. We believe the improved diagnostic accuracy, utility in stress imaging, reduced radiation exposure and potential for quantification of coronary flow reserve provide great promise for flurpiridaz F 18 to become the diagnostic imaging tool of choice for evaluating coronary artery disease in obese patients.”

It must feel good to rise above; and, Lantheus has proven to be a lasting contender in the medical imaging sector. With positive Q1 financials and promising Phase 3 data, the investment community looks forward to further developments from the company.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Symbol Name Price Change % Volume
LNTH Lantheus Holdings Inc. 28.26 0.29 1.04 283,660 Trade



Symbol Last Price Change % Change






What Is Petrolithium?

MGX Minerals explains the advantages of petrolithium and how they are helping to solve future problems today.